Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Carcinoma, Transitional Cell
  • Indoles
  • Pyrroles
  • Urologic Neoplasms
  • Vascular Endothelial Growth Factor Receptor-2

abstract

  • The current multicenter study was limited by premature closure and a small sample size. Maintenance sunitinib did not appear to improve the 6-month progression rate. Open-label sunitinib was found to have only modest activity. The sVEGFR2 level decreased among patients receiving sunitinib.

publication date

  • March 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.28477

PubMed ID

  • 24249435

Additional Document Info

start page

  • 692

end page

  • 701

volume

  • 120

number

  • 5